acf/google-ad-placement

Century Therapeutics, Inc. IPSC reported weaker-than-expected second-quarter results.

Century Therapeutics posted quarterly loss of 56 cents per share, <a href="https://www.benzinga.com/calendars/earnings">missing analysts&rsquo; expectations</a> for a loss of 54 cents per share. The company&rsquo;s sales came in $99,000, missing estimates of $1.14 million.

Century Therapeutics shares fell 1.7% to close at $2.85 on Wednesday.

These analysts made changes to their price targets on Century Therapeutics following earnings announcement.<ul>
	<li>Chardan Capital cut the price target on Century Therapeutics from $19 to $17. Chardan Capital analyst Geulah Livshits maintained a Buy rating.</li>
	<li>HC Wainwright &amp; Co. lowered the price target on Century Therapeutics from $17 to $13. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating on the stock.</li>
	<li>EF Hutton analyst Tony Butler, meanwhile, reiterated Century Therapeutics with a Buy and maintained a $16 price target.</li>
</ul>

&nbsp;

Read This Next: <a href="https://www.benzinga.com/news/earnings/23/08/33696118/disney-alibaba-and-3-stocks-to-watch-heading-into-thursday"> Disney, Alibaba And 3 Stocks To Watch Heading Into Thursday</a>

Earnings

News

Penny Stocks

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

Century Therapeutics, Inc. (NASDAQ: IPSC) reported weaker-than-expected second-quarter results.

These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results - Century Therapeutics (NASDAQ:IPSC)

Lisa Levin

Century Therapeutics

Century Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipsc#NASDAQ">IPSC</a>) reported weaker-than-expected second-quarter results.

PT Changes

IPSC

These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results

Century Therapeutics Inc

Application error: a client-side exception has occurred (see the browser console for more information).